CN112557662B - Colorectal cancer detection kit - Google Patents

Colorectal cancer detection kit Download PDF

Info

Publication number
CN112557662B
CN112557662B CN202110194925.4A CN202110194925A CN112557662B CN 112557662 B CN112557662 B CN 112557662B CN 202110194925 A CN202110194925 A CN 202110194925A CN 112557662 B CN112557662 B CN 112557662B
Authority
CN
China
Prior art keywords
cea
seq
monoclonal antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110194925.4A
Other languages
Chinese (zh)
Other versions
CN112557662A (en
Inventor
王阳
金鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hezhuo Biotechnology Shanghai Co ltd
Original Assignee
Hezhuo Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hezhuo Biotechnology Shanghai Co ltd filed Critical Hezhuo Biotechnology Shanghai Co ltd
Priority to CN202110194925.4A priority Critical patent/CN112557662B/en
Publication of CN112557662A publication Critical patent/CN112557662A/en
Application granted granted Critical
Publication of CN112557662B publication Critical patent/CN112557662B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention relates to the field of tumor immunodetection, in particular to a colorectal cancer detection kit, and also discloses application of an antibody in preparation of a tumor treatment and/or diagnosis reagent. The application of the kit provides an effective tool for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of colon cancer and rectal cancer patients.

Description

Colorectal cancer detection kit
Technical Field
The invention relates to the technical field of immunodetection, and particularly relates to a colorectal cancer detection kit.
Background
Colorectal malignancies are currently one of the most common tumors in the world. In developed countries in europe and america, the incidence rate is second to malignant tumors and third to the world, and men are second to lung cancer and gastric cancer, while women are second to breast cancer and cervical cancer. Colorectal cancer is most common in north america, western european australia, and new zealand, among other countries. In China, the incidence of colorectal cancer is fifth in men and fifth in women. Compared with developed countries, the onset age of colorectal cancer in China is obviously advanced, and the median onset age is about 45 years old. Moreover, the incidence of colorectal cancer continues to be strongly rising with the recent improvement of living standard.
Carcinoembryonic antigen (CEA) is a soluble glycoprotein with a complex structure, a molecular weight of about 200kDa, and is mainly present in the gastrointestinal tract, pancreas and liver of a fetus during the embryonic period, and has a very low postnatal tissue content. CEA levels are abnormally elevated in the serum of patients with gastrointestinal malignancies, breast cancer, carcinomas and other malignancies. The expression of the CEA in colorectal cancer is the highest (60-90%), so that the CEA content can be used as an effective index for prognosis judgment, curative effect observation, tumor focus metastasis or recurrence monitoring and the like of patients with colon cancer and rectal cancer, can be used as an independent prognostic factor, and receives more and more attention.
At present, various anti-CEA antibody patents are published at home and abroad, such as W02004032962, W02011034660, W02012l17002, CN103173417 and the like. Monoclonal antibodies with higher affinity and more favorable properties are still needed. Has important significance for prognosis judgment, curative effect observation and diagnosis and scientific research of monitoring the metastasis or relapse of tumor lesions of patients with colon cancer and rectal cancer.
Disclosure of Invention
The invention aims to provide a CEA antibody which has high affinity and can be used for detecting carcinoembryonic antigen aiming at the defects in the prior art.
The invention provides the following technical scheme:
an anti-CEA monoclonal antibody, consisting of a heavy chain and a light chain, which comprise a variable region and a constant region, respectively, wherein the heavy chain variable region is selected from SEQ ID NO. 7 and the light chain variable region is selected from SEQ ID NO. 8.
The anti-CEA monoclonal antibody heavy and light chain variable region of the invention has 6 complementarity determining regions. The 3 CDR sequences of the heavy chain variable region of the anti-CEA monoclonal antibody are respectively SEQ ID NO 1, SEQ ID NO 2 and SEQ ID NO 3; the variable region of light chain has 3 CDR sequences of SEQ ID NO 4, SEQ ID NO 5 and SEQ ID NO 6.
The heavy and light chains of the anti-CEA monoclonal antibody of the invention further comprise constant regions, and the antibody light chain constant region further comprises murine kappa and lambda chain sequences. The antibody heavy chain constant region further comprises a murine IgG1, IgG2a, IgG2b, or IgG3, or IgA or IgM sequence.
The invention also aims to provide a CEA quantitative detection kit, a preparation method and application thereof. The kit comprises the CEA-recognizing antibody, and is used for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of colon cancer and rectal cancer patients.
The CEA quantitative detection kit comprises an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme-labeled antibody.
The anti-CEA enzyme-labeled antibody is a CEA polyclonal antibody marked by horseradish peroxidase. The preparation method of the polyclonal antibody and the method of the enzyme-labeled antibody are all routine operations in the field.
Further, the quantitative detection kit also comprises a CEA standard substance, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution.
The anti-CEA monoclonal antibody, a CEA standard substance, a horseradish peroxidase labeled anti-CEA polyclonal antibody, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution are respectively put into each reagent bottle, and each reagent bottle is fixed by a sponge bracket and is arranged in a kit body together with an ELISA plate and a sealing plate membrane which are coated by the CEA antibody.
Advantageous effects
The invention has the following beneficial effects: provides a new CEA antibody with high affinity, which can be used for carcinoembryonic antigen detection; the CEA detection kit established by the antibody of the invention has the advantages of simple and easy operation, quick and sensitive detection, simple and popular enzyme labeling instrument and low price, and provides an effective tool for prognosis judgment, curative effect observation and diagnosis of monitoring metastasis or relapse of tumor lesions of patients with colon cancer and rectal cancer.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention.
FIG. 1 mouse monoclonal antibody subtype identification.
FIG. 2 anti-CEA antibody specificity: does not cross react with MA and NCA.
FIG. 3 shows a standard curve for detecting carcinoembryonic antigen CEA by the carcinoembryonic antigen detection kit of the present invention.
Detailed Description
The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
Example 1 anti-CEA antibody preparation and purification
Culturing CHO cells stably expressing CEA in DMEM medium, and culturing 107CHO-CEA+Cells were injected intraperitoneally with Freund's complete adjuvant in female Balb/c mice for primary immunization followed by 10 more times every 2 weeks7CHO-CEA+Cells were injected intraperitoneally into the female Balb/c mice and immunization was continued. Finally, the last immunization is carried out 3 days before the fusion with the myeloma cells, and the last immunization is 107CHO-CEA+Cells are immunized intravenously. Spleen cells of immunized Balb/c mice were fused with a myeloma Sp2/0 cell line, and the fused cells were diluted to an appropriate concentration in Iscove's medium (0.1 mM hypoxanthine, 0.4. mu.M aminopterin and 16. mu.M thymidine) containing 10% serum, and then cultured in a 96-well plate. After 10 days, cell supernatants were taken and primary cultures showing positive reaction with recombinant CEA protein in the supernatants were examined by high throughput ELISA. And diluting the hybridoma cells in the hole for subcloning, and screening by an ELISA method to finally obtain a positive hybridoma cell strain. After expansion culture, the hybridoma cells were cryopreserved.
BALB/c mice were injected intraperitoneally with 0.5 ml/mouse, 1 week before hybridoma inoculation. After 1 week, each mouse was inoculated intraperitoneally at about 1X106(ii) individual hybridoma cells; and after 7-10 days, collecting ascites. Centrifuging ascites at 10000 Xg for 30min, removing precipitate, salting out with 50% ammonium sulfate, coarse extracting, dissolving with PBS, and dialyzing with flowing water for 5 hr; dialyzing and equilibrating with 0.1mol/L phosphate buffer (pH 8.0) overnight; and (3) loading, eluting the hybrid protein by using 0.1mol/L phosphate buffer solution (pH8.0), eluting by using citrate eluents with different pH values, collecting elution peaks in sections, concentrating, analyzing and purifying the purity of the monoclonal antibody by 10 percent SDS-PAGE, and determining the titer by an indirect ELISA method. Through indirect ELISA detection, the titer of 8 mAbs can reach 1: 108。
Example 2 anti-CEA antibody subtype identification
The subtype of the anti-CEA monoclonal antibody Cab-1003 obtained in example 1 was identified by ELISA (kit purchased from Proteintech). The microplate provided in the kit was already pre-coated with specific antibodies against mouse IgG1, IgG2a, IgG2b, IgG3, IgA, IgM, kappa light chain, lambda light chain, and the anti-CEA antibody sample Cab-1003 purified in example 1 was added to the sample well at 50. mu.l per well without incubation. Adding 1X goat anti-mouse IgA + IgM + IgG-HRP into sample wells, mixing the sample wells with 50 μ l each, and incubating for 1 h. And (4) deducting liquid in the holes, adding 1XPBST to wash the holes for 3 times, and absorbing the excessive moisture by absorbent paper. Adding color development solution, and developing 100 μ l per well in dark at room temperature for 15 min. The color reaction was stopped by adding 100. mu.l of stop solution. The OD value at 450nm is detected by a microplate reader, and the result is shown in figure 1, wherein the heavy chain subtypes of the obtained anti-CEA monoclonal antibody Cab-1003 are all IgG2a, and the light chain thereof is Kappa.
EXAMPLE 3 monoclonal antibody sequencing
After the hybridoma cell strain corresponding to Cab-1003 is recovered, the hybridoma cell strain is cultured until the total amount is 107 The cells were centrifuged at 1000rpm for 5min to collect the cells, and RNA was extracted. TRNzol-A + was added to the cell pellet for lysis and allowed to stand at room temperature for 15 min. Mu.l chloroform was added to each ml of TRNzol-A +, vortexed for 15 seconds, and allowed to stand for 3 minutes. 13000 rpm, 4 ℃ for 10 minutes, Trizol-A + cell solution is divided into three layers: transferring the water phase dissolved with the RNA into a centrifuge tube, adding isopropanol with the same volume into the water phase, uniformly mixing, and standing at room temperature for 25 minutes. 13000 rpm, 4 ℃ for 10 minutes, discard the waste liquid to get the bottom RNA precipitation. After washing the RNA pellet twice with 75% ethanol, the RNA was dissolved in PEDC water and stored at-80 ℃. Synthesizing first chain cDNA by reverse transcription kit SMARTERRACE, and amplifying antibody variable region DNA sequence corresponding to hybridoma cell by using the first chain cDNA as subsequent template. Designing specific nested PCR primer, the primer sequence used in the amplification reaction is complementary with the first frame region and the constant region of the antibody variable region, and amplifying the target gene by adopting a conventional PCR method. Sequencing the amplified product to obtain a heavy chain variable region sequence SEQ ID NO: 7 and the light chain may beVariable region sequence SEQ ID NO: 8; the 3 CDR sequences of the heavy chain variable region of the antibody are respectively SEQ ID NO 1, SEQ ID NO 2 and SEQ ID NO 3; the variable region of light chain has 3 CDR sequences of SEQ ID NO 4, SEQ ID NO 5 and SEQ ID NO 6.
Example 4 identification of antibody specificity
The monoclonal antibody purified in example 1 was cross-reacted with the CEA, MA, NCA coated ELISA plate by indirect ELISA, and the specificity was analyzed. The specific experimental process is to coat CEA, MA and NCA (all from Fitzgerald) respectively at a concentration of 0.1mg/ml, add the antibody obtained in example 1 to three different coating antigens respectively, and detect the degree of cross reaction by indirect ELISA. As shown in FIG. 2, the anti-CEA monoclonal antibody Cab-1003 reacted only with CEA and did not cross-react with MA and NCA.
Example 5 affinity assay for anti-CEA antibodies
An antibody capture Antibody (AHC) is coated on the surface of a CM5 chip by means of amino coupling, chip activation buffer solution N-ethyl-N' - (3-dimethylaminopropyl) -carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS), AHC and ethanolamine for blocking are prepared according to the specifications of an amino coupling kit and an anti-capture kit, a coating program in a Biacore3000 system is selected, and AHC amino is coupled on the surface of a CM5 chip. The anti-CEA antibody Cab-1003 obtained in example 1 was captured on the chip surface. The antibody was diluted to 1. mu.g/mL with HBS-EP + buffer, set to a flow rate of 5. mu.L/min, and coated to a response value of 300 RU. CEA antigen was set up in 7 different concentration gradients and serially diluted in HBS-EP buffer in 2-fold gradients from 200nM to 3.125 nM. The flow rate of CEA antigen was set at 30. mu.L/min and the binding time was set at 3 min. The flow rate of HBS-EP + buffer is set to be 30 mu L/min, and the dissociation time is set to be 10 min. Use of 3M MgCl2As a regeneration buffer, the chip was regenerated according to the regeneration procedure. In addition, affinity assay was performed according to the same procedure with reference to antibody sanofi (antibody light and heavy chain variable region sequences are shown in SEQ ID NO:9, 10, respectively). Calculation of binding Rate (K) by Simultaneous fitting of binding and dissociation sensorgramsa) And dissociation Rate (K)d). Equilibrium dissociation constant (K)d) Using dissociation rate (K)d) Rate of binding (K)a) And (4) calculating. The results are shown in table one: compared with the control antibody, the antibody of the invention has higher affinity, and the affinity KDThe value reaches 3.51x10-9M。
Watch 1
Antibodies Ka（1/Ms） Kd（1/s） KD(M)
Cab-1003 6.59x104 2.31x10-4 3.51x10-9
sanofi 4.11x104 1.91x10-3 4.65x10-8
Example 6 preparation of CEA quantitative immunoassay kit
Preparing enzyme label plate
The anti-CEA monoclonal antibody Cab-1003 obtained in example 1 was diluted to 0.5. mu.g/ml with 0.01M phosphate buffer solution, and the pH was 7.0 to 7.4 to obtain a coating solution. Adding 3% of skimmed milk powder into 0.01M phosphate buffer solution with the pH value of 7.0-7.4 to prepare confining liquid. Adding the prepared coating solution into the hole of an enzyme-labeled plate, adding 100 mu L of the coating solution into each hole, coating the enzyme-labeled plate overnight at 4 ℃, adding the prepared confining solution into the hole of the enzyme-labeled plate, adding 100 mu L of the confining solution into each hole, placing the hole in a 37 ℃ incubator for 30 minutes, taking the enzyme-labeled plate out of the incubator, removing the confining solution, and keeping the temperature at 37 ℃ for 30 minutes.
(II) preparing enzyme-labeled antibody solution
Immunizing a rabbit with the CEA antigen to obtain an anti-CEA polyclonal antibody, and labeling the anti-CEA polyclonal antibody with horseradish peroxidase to obtain an enzyme-labeled antibody. Firstly, weighing a proper amount of HRP enzyme, dissolving the HRP enzyme in triple distilled water, adding a newly-prepared sodium periodate solution, uniformly mixing, and then placing at 4 ℃ for 30 min; adding ethylene glycol solution, and standing at room temperature for 30 min; adding appropriate amount of purified antibody, mixing, adjusting pH to 9.0, standing at 4 deg.C overnight; adding sodium borohydride, mixing, and standing at 4 deg.C for 2 hr; adding the enzyme-labeled antibody mixed solution into an isovolumetric saturated ammonium sulfate solution, and standing at 4 ℃ for 30 min; after centrifugation, the mixture was dialyzed overnight against a phosphate buffer solution of pH 7.4.
(III) preparing CEA standard substance
CEA antigen: commercially available from Fitzgerald corporation.
(IV) preparation of concentrated Wash solution (20X 0.01M PBS)
Mixing 96 parts of sodium chloride, 2.4 parts of potassium chloride, 42.96 parts of disodium hydrogen phosphate dodecahydrate, 2.88 parts of potassium dihydrogen phosphate, 200.05 parts of tween-and 1000 parts of ultrapure water uniformly to obtain the finished product.
(V) substrate solution (TMB)
TMB Tetramethylbenzidine (3,3 ', 5, 5' -Tetramethylbenzidine), available from Tiangen, Beijing.
(VI) preparing stop solution (2mol/L sulfuric acid solution)
Diluting concentrated sulfuric acid and ultrapure water by 1: 8 to prepare stop solution.
Example 7 determination of the detection Range of the CEA quantitative immunoassay kit
CEA antigen was diluted with artificial serum in a gradient of 1000, 400, 200, 100, 50, 20, 5, 1, 0.2 ng/ml. Detection was performed using the kit of example 6. And (3) drawing a standard curve by taking the CEA antigen concentration as an abscissa and the corresponding A450 as an ordinate to obtain a fitting regression equation, and selecting the CEA antigen concentration range with the best linear relation as the optimal detection range of the detection reagent. The final data are shown in fig. 3, and the detection results show that when the CEA concentration is 1-400ng/ml, the linear relationship with the corresponding a450 value is good, R2 = 0.998, and the regression equation is: y =0.0038x +0.2201, with the lowest detection line being 0.15 ng/ml.
Sequence listing
<110> Beijing Vast Mei Biotechnology Ltd
<120> colorectal cancer detection kit
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Asp Ala Gly Met Ser
1 5
<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Asp Ile Ser Cys Lys Ala Gly Asn Thr Ala Gly Tyr Asp Phe Lys Gly
1 5 10 15
<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Arg Ala Asn Tyr Gly Tyr Val Phe Asp Val
1 5 10
<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Ser Ala Ser Ser Gln His Ser Asp Ile Asn Leu His
1 5 10
<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Gly Thr Asn Ser Ile Leu Lys Ser Thr Gly Asp
1 5 10
<210> 6
<211> 13
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gly Val Gly Gln Gln Asn Ile Lys Glu Phe Pro Tyr Ala
1 5 10
<210> 7
<211> 118
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ala
20 25 30
Gly Met Ser Trp Val Arg Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45
Gly Asp Ile Ser Cys Lys Ala Gly Asn Thr Ala Gly Tyr Asp Phe Lys
50 55 60
Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Val Tyr Met
65 70 75 80
Glu Phe Arg Ser Leu Thr Leu Glu Asp Ser Ala Ile Tyr Phe Cys Ala
85 90 95
Arg Arg Ala Asn Tyr Gly Tyr Val Phe Asp Val Trp Gly Gln Gly Thr
100 105 110
Ile Phe Thr Val Ser Ser
115
<210> 8
<211> 115
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Asp Leu Val Val Thr Gln Ser Ser Ser Ala Ser Phe Ser Leu Gly Ala
1 5 10 15
Ser Ala Lys Leu Thr Cys Ser Ala Ser Ser Gln His Ser Asp Ile Asn
20 25 30
Leu His Trp Tyr Gln Gln Gln Pro Leu Lys Pro Pro Lys Tyr Val Met
35 40 45
Glu Gly Thr Asn Ser Ile Leu Lys Ser Thr Gly Asp Gly Ile Pro Asp
50 55 60
Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Thr Ile Ser
65 70 75 80
Asn Ile Gln Pro Glu Asp Glu Ala Ile Tyr Ile Cys Gly Val Gly Gln
85 90 95
Gln Asn Ile Lys Glu Phe Pro Tyr Ala Phe Gly Gly Gly Thr Lys Val
100 105 110
Thr Val Leu
115
<210> 9
<211> 120
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Ser Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Ser Tyr
20 25 30
Asp Met Ser Trp Val Arg Gln Thr Pro Glu Arg Gly Leu Glu Trp Val
35 40 45
Ala Tyr Ile Ser Ser Gly Gly Gly Ile Thr Tyr Ala Pro Ser Thr Val
50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala His Tyr Phe Gly Ser Ser Gly Pro Phe Ala Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120
<210> 10
<211> 107
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Phe Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Val
35 40 45
Tyr Asn Thr Arg Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Gly Thr Pro Phe
85 90 95
Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105

Claims (8)

1. A CEA antigen quantitative determination kit is characterized in that: comprises an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme labeled antibody; the anti-CEA monoclonal antibody includes a heavy chain variable region comprising SEQ ID NO:1, CDR1 shown in SEQ ID NO:2 and CDR2 shown in SEQ ID NO:3, and a light chain variable region comprising the CDR3 of SEQ ID NO:4, CDR1 shown in SEQ ID NO:5 and the CDR2 shown in SEQ ID NO:6, CDR3 shown.
2. A CEA antigen quantitative determination kit is characterized in that: comprises an enzyme label plate coated by an anti-CEA monoclonal antibody and an anti-CEA enzyme labeled antibody; the anti-CEA monoclonal antibody includes a heavy chain variable region comprising SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8.
3. The kit for quantitatively detecting a CEA antigen according to claim 1 or 2, characterized in that: the anti-CEA enzyme-labeled antibody is a horseradish peroxidase-labeled anti-CEA polyclonal antibody.
4. The CEA antigen quantitative determination kit according to claim 3, characterized in that: the quantitative detection kit also comprises a CEA standard substance, a concentrated washing solution, a sample diluent, a substrate solution and a stop solution.
5. A monoclonal antibody to a CEA antigen, characterized by: the monoclonal antibody includes a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:1, CDR1 shown in SEQ ID NO:2 and CDR2 shown in SEQ ID NO:3, and a light chain variable region comprising the CDR3 of SEQ ID NO:4, CDR1 shown in SEQ ID NO:5 and the CDR2 shown in SEQ ID NO:6, CDR3 shown.
6. A monoclonal antibody to a CEA antigen, characterized by: the monoclonal antibody includes a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8.
7. Use of the monoclonal antibody of claim 5 or 6 for the preparation of a reagent for detecting a CEA antigen in a cancer patient.
8. Use according to claim 7, characterized in that: the cancer is colon cancer and rectal cancer.
CN202110194925.4A 2021-02-22 2021-02-22 Colorectal cancer detection kit Active CN112557662B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110194925.4A CN112557662B (en) 2021-02-22 2021-02-22 Colorectal cancer detection kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110194925.4A CN112557662B (en) 2021-02-22 2021-02-22 Colorectal cancer detection kit

Publications (2)

Publication Number Publication Date
CN112557662A CN112557662A (en) 2021-03-26
CN112557662B true CN112557662B (en) 2021-07-06

Family

ID=75034418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110194925.4A Active CN112557662B (en) 2021-02-22 2021-02-22 Colorectal cancer detection kit

Country Status (1)

Country Link
CN (1) CN112557662B (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032962A1 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
CN1646567A (en) * 2002-04-09 2005-07-27 默克专利有限公司 Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine
CN101607985A (en) * 2008-12-24 2009-12-23 中国科学院生物物理研究所 The monoclonal antibody of anti-people CEA comprises its composition, and uses thereof
CN102482701A (en) * 2009-09-16 2012-05-30 免疫医疗公司 Class I Anti-CEA antibodies and uses thereof
WO2012117002A1 (en) * 2011-03-02 2012-09-07 Roche Glycart Ag Cea antibodies
CN104628859A (en) * 2015-01-26 2015-05-20 佳德资本投资管理（Bvi）有限公司 Anti-human carcino-embryonic antigen antibody as well as coding gene and application thereof
CN108659130A (en) * 2018-05-28 2018-10-16 长春力太生物技术有限公司 A kind of anti-carcinoembryonic antigen nano antibody of high-affinity and its application
CN110713539A (en) * 2019-09-23 2020-01-21 华道(上海)生物医药有限公司 Anti-carcinoembryonic antigen antibody and preparation method and application thereof
CN111363037A (en) * 2020-05-26 2020-07-03 北京瀚梅生物科技有限公司 Disease detection kit containing antibody specifically binding AFP protein
CN111533805A (en) * 2016-12-04 2020-08-14 深圳市国创纳米抗体技术有限公司 High-affinity nano antibody for resisting carcinoembryonic antigen and application thereof
WO2020208124A1 (en) * 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
CN111995688A (en) * 2020-08-13 2020-11-27 金鑫 Bispecific chimeric antigen receptor targeting CD123 and NKG2D ligands and application thereof
CN112063640A (en) * 2019-06-11 2020-12-11 南京艾德免疫治疗研究院有限公司 Chimeric antigen receptor targeting humanized CEA and uses thereof
WO2020259550A1 (en) * 2019-06-26 2020-12-30 江苏恒瑞医药股份有限公司 Anti-cea antibody and application thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646567A (en) * 2002-04-09 2005-07-27 默克专利有限公司 Anti-idiotype anti-CEA antibody molecules and its use as cancer vaccine
WO2004032962A1 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
CN101607985A (en) * 2008-12-24 2009-12-23 中国科学院生物物理研究所 The monoclonal antibody of anti-people CEA comprises its composition, and uses thereof
CN102482701A (en) * 2009-09-16 2012-05-30 免疫医疗公司 Class I Anti-CEA antibodies and uses thereof
WO2012117002A1 (en) * 2011-03-02 2012-09-07 Roche Glycart Ag Cea antibodies
CN104628859A (en) * 2015-01-26 2015-05-20 佳德资本投资管理（Bvi）有限公司 Anti-human carcino-embryonic antigen antibody as well as coding gene and application thereof
CN111533805A (en) * 2016-12-04 2020-08-14 深圳市国创纳米抗体技术有限公司 High-affinity nano antibody for resisting carcinoembryonic antigen and application thereof
CN108659130A (en) * 2018-05-28 2018-10-16 长春力太生物技术有限公司 A kind of anti-carcinoembryonic antigen nano antibody of high-affinity and its application
WO2020208124A1 (en) * 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
CN112063640A (en) * 2019-06-11 2020-12-11 南京艾德免疫治疗研究院有限公司 Chimeric antigen receptor targeting humanized CEA and uses thereof
WO2020259550A1 (en) * 2019-06-26 2020-12-30 江苏恒瑞医药股份有限公司 Anti-cea antibody and application thereof
CN110713539A (en) * 2019-09-23 2020-01-21 华道(上海)生物医药有限公司 Anti-carcinoembryonic antigen antibody and preparation method and application thereof
CN111363037A (en) * 2020-05-26 2020-07-03 北京瀚梅生物科技有限公司 Disease detection kit containing antibody specifically binding AFP protein
CN111995688A (en) * 2020-08-13 2020-11-27 金鑫 Bispecific chimeric antigen receptor targeting CD123 and NKG2D ligands and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Modeling the Anti-CEA Antibody Combining Site by Homology and Conformational Search;Maria T. Mas 等;《PROTEINS: Structure, Function, and Genetics》;19921231;第14卷;第483-498页 *
联合检测血清标志物CYFRA21-1、NSE、CEA对肺癌的鉴别诊断意义;金鑫;《中国临床研究》;20110630;第24卷(第6期);第521-522页 *

Also Published As

Publication number Publication date
CN112557662A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
US9823251B2 (en) Anti-Uroplakin II antibodies systems and methods
CN112094348B (en) Anti-human Tim3 antibody or functional fragment thereof and application thereof
CN116375856A (en) anti-Tau protein monoclonal antibody 1A5-47H7, product based on same and application
CN111363037B (en) Disease detection kit containing antibody specifically binding AFP protein
CN107690439B (en) IGF-1R antibodies and uses thereof for diagnosing cancer
CN112557662B (en) Colorectal cancer detection kit
CN110105449B (en) Antibody specifically binding VEGF and application
CN112876565B (en) Colorectal cancer detection kit
CN112710835B (en) Reproductive system disease detect reagent box
JPWO2009044561A1 (en) Anti-proNT / NMN monoclonal antibody
CN112646037B (en) anti-CD 105 specific monoclonal antibody and application thereof
CN110031616B (en) Detection kit for auxiliary diagnosis of diseases
CN110133278B (en) In-vitro kit for detecting human VEGF protein expression level
CN112500488B (en) Cancer detection kit
CN112684175B (en) Kit for detecting ovarian cancer
CN110579610A (en) Kit for detecting V-domain immunosuppressive factor activated by T cells
CN112694533B (en) Reproductive system disease detection kit
CN110596369A (en) Kit for detecting human TIM-3 expression level
CN111410689A (en) Monoclonal antibody 69E2 for resisting HPV16E7 protein, hybridoma cell strain, and preparation method and application thereof
CN113186284B (en) Nucleic acid-antibody dual cancer detection kit
CN113249445B (en) Nucleic acid-antibody dual cancer detection kit
WO2014146487A1 (en) Anti-cell surface ectopic expression monoclonal antibody, preparation method and use thereof
CN109776679B (en) Antibody of serine protease inhibitor SPINK1, and preparation method and application thereof
CN116284411B (en) Antibody against recombinant human coagulation factor VIII-Fc fusion protein and application thereof
CN110156891B (en) Antibody capable of efficiently and quickly binding VEGF and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Room 321, traditional Chinese Medicine Innovation Park, 199 GuoShouJing Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: BASETRA MEDICAL TECHNOLOGY CO.,LTD.

Address before: 201-134, 2 / F, building 23, courtyard 8, Dongbei Wangxi Road, Haidian District, Beijing

Applicant before: Beijing Hanmei Biotechnology Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A Colorectal Cancer Detection Kit

Effective date of registration: 20231201

Granted publication date: 20210706

Pledgee: Industrial Bank Co.,Ltd. Shanghai Changning sub branch

Pledgor: BASETRA MEDICAL TECHNOLOGY CO.,LTD.

Registration number: Y2023310000796

PE01 Entry into force of the registration of the contract for pledge of patent right